Brunelli Steven M
Renal, Electrolyte, and Hypertension Division and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Am J Kidney Dis. 2009 Mar;53(3):448-56. doi: 10.1053/j.ajkd.2008.09.022. Epub 2008 Dec 19.
Case reports and series have suggested an association between oral sodium phosphate bowel preparations and kidney injury. Results of analytic studies have been mixed.
Systematic review and meta-analysis.
SETTING & POPULATION: Patients receiving sodium phosphate bowel preparations (or comparators) in anticipation of colonoscopy.
Primary data reports of controlled studies of the effects of oral sodium phosphate versus comparator on kidney function.
Receipt of oral sodium phosphate bowel purgative.
Random-effects pooled odds ratio for kidney injury in oral sodium phosphate-treated patients.
Seven studies met criteria for inclusion. Significant heterogeneity existed in the populations under study (colonoscopy indication, baseline kidney function, and demographics), methods used (control group and use of prophylactic hydration), definition of kidney injury used (timing and magnitude), and results observed. The pooled odds ratio for kidney injury in oral sodium phosphate-treated patients ranged from 1.08 (95% confidence interval, 0.71 to 1.62) to 1.22 (95% confidence interval, 0.77 to 1.92). No obvious study- or patient-level factors that explained interstudy heterogeneity were identified.
Few studies, each of limited quality.
Based on existing data, it is not possible to discern whether there is an association between receipt of oral sodium phosphate and kidney injury. Future investigation should be aimed at clarifying this association and examining the roles of prophylactic hydration and baseline kidney function on any imposed risk. Future work would be greatly enhanced by a standardized definition of incident kidney injury.
病例报告及系列病例研究提示口服磷酸钠肠道准备剂与肾损伤之间存在关联。分析性研究的结果不一。
系统评价与荟萃分析。
接受磷酸钠肠道准备剂(或对照剂)以准备结肠镜检查的患者。
关于口服磷酸钠与对照剂对肾功能影响的对照研究的原始数据报告。
接受口服磷酸钠肠道泻药。
口服磷酸钠治疗患者发生肾损伤的随机效应合并比值比。
七项研究符合纳入标准。在所研究的人群(结肠镜检查适应证、基线肾功能和人口统计学特征)、所采用方法(对照组及预防性补液的使用)、所采用的肾损伤定义(时间和程度)以及观察到的结果方面存在显著异质性。口服磷酸钠治疗患者发生肾损伤的合并比值比在1.08(95%置信区间为0.71至1.62)至1.22(95%置信区间为0.77至1.92)之间。未发现能解释研究间异质性的明显研究水平或患者水平因素。
研究数量少,且每项研究质量有限。
基于现有数据,无法确定口服磷酸钠与肾损伤之间是否存在关联。未来的研究应致力于阐明这种关联,并探讨预防性补液和基线肾功能在任何潜在风险中的作用。采用标准化的新发肾损伤定义将极大地促进未来的研究工作。